PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has

Read More

ToxNav ® validation data published

Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal

Read More

Colorectal cancer in the Covid-19 era

Professors David and Rachel Kerr’s proposed colorectal cancer treatment guidelines for patients during the COVID-19 era. AIMS To reduce the

Read More

OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients

Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology

Read More

Oxford Cancer Biomarkers appoints a Medical Science Liaison Manager to strengthen operations and support continued growth

Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen

Read More

Oxford Cancer Biomarkers hires two Senior Operations and Quality Control Specialists to help manage continued growth

For immediate release: 22 August 2019 Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to

Read More

OCB appoints James Otter as new CEO

Oxford, UK, 15th July 2019:    Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth

Read More

Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity

  Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to

Read More